FDA's Enforcement Guidance Is Now Under Legal Challenge

On July 14, 2026, a group of public health organizations, a pediatrician and a parent filed suit in the United States District Court for the District of Maryland asking the court to vacate the enforcement guidance FDA issued in May 2026 (Complaint, No. 8:26-cv-02767-ABA (D. Md. July 14, 2026)).

The case will be argued on youth access and administrative law. That is not the reason it belongs on a sourcing desk. It belongs there because a large number of ENDS and nicotine pouch products are currently on the US market under that policy rather than under a marketing granted order, and a policy is a different kind of foundation from an order.

What follows sets out what was filed, what the guidance says about itself, and what a buyer can reasonably do with that. It does not predict how the case will come out, and nothing here is a position on the underlying policy question.

What Was Filed on July 14

The document is a complaint for declaratory and injunctive relief, filed in the District of Maryland and docketed as No. 8:26-cv-02767-ABA (Complaint). The organizational plaintiffs are the Campaign for Tobacco-Free Kids, the American Academy of Pediatrics, the American Cancer Society Cancer Action Network, the American Heart Association, the American Lung Association, Parents Against Vaping E-Cigarettes and Truth Initiative, joined by a pediatrician and a parent (Complaint).

The complaint pleads six counts. It alleges that the guidance is not in accordance with law and exceeds FDA's statutory authority, that it is arbitrary and capricious, that it violates the Administrative Procedure Act's notice-and-comment requirement, that it was adopted contrary to the Federal Food, Drug, and Cosmetic Act's public participation requirement, that it was adopted through a process contrary to FDA's own regulations, and that it is ultra vires (Complaint). The plaintiffs "seek vacatur of the Guidance and other declaratory and injunctive relief" (Complaint).

Every one of those is an allegation. None has been tested, and the guidance remains in effect. The complaint also points to earlier litigation in the same district over a 2017 guidance, stating that "A court in this district invalidated the 2017 Guidance, determining that FDA had both exceeded its statutory authority and violated the APA by issuing the 2017 Guidance without following notice-and-comment rulemaking" (Complaint). That is the plaintiffs' framing of the precedent, offered here as their argument rather than as a forecast.

What the Guidance Says About Itself

The more useful document is the guidance, because what it says about its own limits does not depend on how the litigation ends.

It is titled "Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization", it was issued by the Center for Tobacco Products in May 2026, and its notice of availability was published on May 12, 2026 (91 Fed. Reg. 25983). Every page of it carries the heading "Contains Nonbinding Recommendations" (FDA guidance).

It is also unambiguous about the legal status of the products it covers. In its own words, the FD&C Act provides that new tobacco products may not legally be marketed without premarket authorization, and "Accordingly, all new tobacco products on the market without authorization are illegally marketed products" (FDA guidance). The guidance describes an enforcement priority. It does not make anything lawful.

Two further sentences deserve to be read by anyone treating the policy as a stable position. FDA writes that "Providing this information does not guarantee that FDA will not pursue enforcement, on a case-by-case basis, against a particular product" (FDA guidance). And it writes that "The fact that an ENDS or nicotine pouch product falls within this enforcement policy in this guidance in no way has a bearing on whether the tobacco product is likely to receive premarket authorization" (FDA guidance).

That second sentence is the one most often lost in summary. Inclusion in the policy is not a signal about the eventual decision on the application. It is not a preliminary finding, and it is not a queue position.

The Safe Harbor Has a Condition

The policy is also conditional, and the condition is where sourcing enters.

FDA states that for ENDS and nicotine pouch products marketed without authorization, it generally does not intend to prioritize enforcement of the premarket authorization requirement where the product is subject to an application that is pending and "has been accepted and filed", or is subject to a supplemental application accepted and pending for more than 180 days, with an additional condition for nontobacco-flavored ENDS products that the application include the data necessary to evaluate whether the product is appropriate for the protection of the public health (FDA guidance).

Accepted and filed is a threshold, not a formality. FDA explains that "In FDA's experience thus far, many applications have been administratively incomplete to the extent that they received a refuse to accept (RTA) or refuse to file (RTF) determination and did not proceed to scientific review", and it lists examples of inadequate information including "lack of full tobacco product identification", "lack of manufacturing information", "lack of test method information and validation", and "lack of information on all ingredients, constituents, chemicals, and additives" (FDA guidance).

Read that list from a supplier's side of the table. Product identification, manufacturing information, test methods and their validation, and the full ingredient and constituent picture are largely assembled from what an ingredient supplier provides. An application that cannot clear the filing threshold does not sit inside the enforcement policy at all, so a documentation gap is not only a delay to authorization. It can be the difference between being inside the policy and outside it.

What that documentation set has to contain is a subject in its own right, and it is covered in what the May 2026 guidance means for nicotine supplier documentation. This post will not repeat it.

Three Things That Are True at Once

For a buyer trying to plan, the position is best held as three simultaneous facts rather than as a prediction.

First, the products covered by the policy are, in FDA's own description, illegally marketed products that the agency is choosing not to prioritize for enforcement (FDA guidance). Their presence on the shelf reflects an enforcement decision rather than a grant of authorization.

Second, the agency has reserved its position twice over, saying the policy guarantees nothing against case-by-case enforcement and carries no implication about whether authorization will follow (FDA guidance).

Third, the policy itself is now the subject of a request that a court vacate it (Complaint).

None of that tells anyone what will happen, and this post will not guess. Litigation outcomes and timelines are not forecastable from a complaint, and a reader who wants a probability is asking a question no honest source can answer. What the three facts together do support is a planning posture: treat a product's position under the policy as a variable with an uncertain end date, rather than as a settled status that can be assumed through a supply agreement's term.

What This Means for a Nicotine Buyer

The practical work is mostly knowing what you are supplying into.

Start by separating the book. For each product line you supply, establish whether the finished product holds a marketing granted order or is on the market under the enforcement policy. Those are different risk profiles and they should not sit in the same column of a forecast. Where a customer is under the policy, the questions worth asking are whether the application has actually been accepted and filed, and whether anything in the documentation you supply is a live deficiency.

Second, keep your own contribution current rather than archived. FDA's list of filing failures is dominated by identification, manufacturing, method validation and ingredient and constituent information (FDA guidance), which is documentation that goes stale when a specification, a method or a site changes and nobody updates the file.

Third, resist reading the public list as a status symbol. FDA says it intends to update the webpage on a rolling basis to reflect changes in manufacturer status, including the removal of manufacturers and products that no longer fall under the policy (FDA guidance). Appearing on it is a description of where a product currently sits, not a credential.

The broader enforcement picture, including what FDA has actually acted on, is in FDA enforcement trends for unauthorized nicotine products, and the relationship between a nicotine source and an application is in how your nicotine source affects FDA submissions.

If the useful next step is checking whether the documentation behind a material you already buy would survive a filing review, our technical documents library lists specifications, methods of analysis and certificates of analysis by product and document type. Questions about a specific product's regulatory position belong with regulatory counsel, and this post is not a substitute for that advice.

Frequently Asked Questions